Biochemical biomarkers of knee osteoarthritis progression: Results from the FNIH biomarkers consortium progress OA study
Biomarker associations were consistent with Phase I findings, but predictive performance remained modest. Future work in the FNIH OA Biomarkers consortium project will focus on evaluating short term changes in biomarkers to assess their potential for monitoring treatment efficacy.
Authors
- Leticia A. Deveza (ORCID: https://orcid.org/0000-0002-2766-7142)
- Anne‐Christine Bay‐Jensen (ORCID: https://orcid.org/0000-0001-7952-9297)
- C. Ladel (ORCID: https://orcid.org/0000-0001-8657-6219)
- Douglas Robinson (ORCID: https://orcid.org/0000-0003-3500-7678)
- Nigel Arden (ORCID: https://orcid.org/0000-0002-3452-3382)
- Christopher J. Swearingen (ORCID: https://orcid.org/0000-0003-4262-4906)
- M.A. Karsdal (ORCID: https://orcid.org/0000-0001-5026-8740)
- Thomas A. Perry (ORCID: https://orcid.org/0000-0002-0499-3033)
- Virginia B. Kraus (ORCID: https://orcid.org/0000-0001-8173-8258)
- David John Hunter (ORCID: https://orcid.org/0000-0003-3197-752X)
- Jamie E. Collins (ORCID: https://orcid.org/0000-0001-8413-007X)
Institutions
- Brigham and Women's Hospital (US)
- Duke University (US)
- Nuffield Orthopaedic Centre (GB)
- Ono Pharmaceutical (United States) (US)
- Institute for Musculoskeletal Health (AU)
- Arthritis UK (GB)
- Nordic Bioscience (Denmark) (DK)
- Io Therapeutics (United States) (US)
Publication Details
- Journal
- Osteoarthritis and Cartilage Open
- Published
- 2025-09-05
- DOI
- https://doi.org/10.1016/j.ocarto.2025.100677
- Citations
- 5
- Primary Topic
- Osteoarthritis Treatment and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 8.34
Funders
- Arthritis Foundation
- Pfizer
- Novartis
- American Society for Pharmacology and Experimental Therapeutics
- Merck KGaA